An ahemolytic pneumolysin of streptococcus pneumoniae manipulates human innate and CD4+ T-cell responses and reduces resistance to colonization in mice in a serotype-independent manner

Journal of Infectious Diseases

Volumn 210, Issue 10, 2014, Pages 1658-1669

  Nadeem Khan, M ^a   Coleman, John Robert ^b   Vernatter, Joshua ^a   Varshney, Avanish Kumar ^a   Dufaud, Chad ^a   Pirofski, Liise Anne ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b FARMINGDALE STATE COLLEGE   (United States)

Author keywords

apoptosis; colonization; dendritic cell; invasion; mice; pneumolysin; serotype; Streptococcus pneumoniae; T cell.

Indexed keywords

AHEMOLYTIC PNEUMOLYSIN; INTERLEUKIN 17; PNEUMOLYSIN; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; PLY PROTEIN, STREPTOCOCCUS PNEUMONIAE; STREPTOLYSIN; VIRULENCE FACTOR;

ADAPTIVE IMMUNITY; ANIMAL CELL; APOPTOSIS; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; HOST RESISTANCE; HUMAN; HUMAN CELL; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; MALE; MEMORY T LYMPHOCYTE; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; ANIMAL; C57BL MOUSE; CELL CULTURE; CLASSIFICATION; DRUG EFFECTS; GENETICS; IMMUNE EVASION; IMMUNOLOGY; PATHOGENICITY;

ANIMALS; BACTERIAL PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; HUMANS; IMMUNE EVASION; MALE; MICE, INBRED C57BL; SEROGROUP; STREPTOCOCCUS PNEUMONIAE; STREPTOLYSINS; VIRULENCE FACTORS;

EID: 84912062036     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu321     Document Type: Article

References (50)

1. Ogunniyi AD, LeMessurier KS, Graham RM, et al. Contributions of pneumolysin, pneumococcal surface protein A (PspA), and PspC to pathogenicity of Streptococcus pneumoniae D39 in a mouse model. Infect Immun 2007; 75:1843-51.
2. Richards L, Ferreira DM, Miyaji EN, Andrew PW, Kadioglu A. The immunising effect of pneumococcal nasopharyngeal colonisation; protection against future colonisation and fatal invasive disease. Immunobiology 2010; 215:251-63.
3. Malley R, Henneke P, Morse SC, et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci U S A 2003; 100:1966-71.
4. Witzenrath M, Pache F, Lorenz D, et al. The NLRP3 inflammasome is differentially activated by pneumolysin variants and contributes to host defense in pneumococcal pneumonia. J Immunol 2011; 187:434-40.
5. Melin M, Trzcinski K, Antonio M, et al. Serotype-related variation in susceptibility to complement deposition and opsonophagocytosis among clinical isolates of Streptococcus pneumoniae. Infect Immun 2010; 78:5252-61.
6. Srivastava A, Henneke P, Visintin A, et al. The apoptotic response to pneumolysin is Toll-like receptor 4 dependent and protects against pneumococcal disease. Infect Immun 2005; 73:6479-87.
7. Paton JC, Lock RA, Hansman DJ. Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae. Infect Immun 1983; 40:548-52.
8. Kadioglu A, Taylor S, Iannelli F, Pozzi G, Mitchell TJ, Andrew PW. Upper and lower respiratory tract infection by Streptococcus pneumoniae is affected by pneumolysin deficiency and differences in capsule type. Infect Immun 2002; 70:2886-90.
9. Berry AM, Yother J, Briles DE, Hansman D, Paton JC. Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect Immun 1989; 57:2037-42.
10. Coleman JR, Papamichail D, Yano M, Garcia-Suarez Mdel M, Pirofski LA. Designed reduction of Streptococcus pneumoniae pathogenicity via synthetic changes in virulence factor codon-pair bias. J Infect Dis 2011; 203:1264-73.
11. Lock RA, Zhang QY, Berry AM, Paton JC. Sequence variation in the Streptococcus pneumoniae pneumolysin gene affecting haemolytic activity and electrophoretic mobility of the toxin. Microb Pathog 1996; 21:71-83.
12. Jefferies JM, Johnston CH, Kirkham LA, et al. Presence of nonhemolytic pneumolysin in serotypes of Streptococcus pneumoniae associated with disease outbreaks. J Infect Dis 2007; 196:936-44.
13. Benton KA, Paton JC, Briles DE. The hemolytic and complement-Activating properties of pneumolysin do not contribute individually to virulence in a pneumococcal bacteremia model. Microb Pathog 1997; 23:201-9.
14. Harvey RM, Ogunniyi AD, Chen AY, Paton JC. Pneumolysin with low hemolytic activity confers an early growth advantage to Streptococcus pneumoniae in the blood. Infect Immun 2011; 79:4122-30.
15. Song JY, Nahm MH, Moseley MA. Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J Korean Med Sc 2013; 28:4-15.
16. Ritchie ND, Mitchell TJ, Evans TJ. What is different about serotype 1 pneumococci? Future Microbiol 2012; 7:33-46.
17. Vanderkooi OG, Church DL, MacDonald J, Zucol F, Kellner JD. Community- based outbreaks in vulnerable populations of invasive infections caused by Streptococcus pneumoniae serotypes 5 and 8 in Calgary, Canada. PLoS One 2011; 6:e28547.
18. Sanz JC, Cercenado E, Marin M, et al. Multidrug-resistant pneumococci (serotype 8) causing invasive disease in HIV+ patients. Clin Microbiol Infect 2011; 17:1094-8.
19. Ahl J, Littorin N, Forsgren A, Odenholt I, Resman F, Riesbeck K. High incidence of septic shock caused by Streptococcus pneumoniae serotype 3-A retrospective epidemiological study. BMC Infect Dis 2013; 13:492.
20. Grabenstein JD, Weber DJ. Pneumococcal serotype diversity among adults in various countries, influenced by pediatric pneumococcal vaccination uptake. Clin Infect Dis 2014; 58:854-64.
21. Bender JM, Ampofo K, Korgenski K, et al. Pneumococcal necrotizing pneumonia in Utah: does serotype matter? Clin Infect Dis 2008; 46:1346-52.
22. Ceyhan M, Ozsurekci Y, Gurler N, et al. Distribution of Streptococcus pneumoniae serotypes that cause parapneumonic empyema in Turkey. Clin Vaccine Immunol 2013; 20:972-6.
23. Croucher NJ, Finkelstein JA, Pelton SI, et al. Population genomics of post-vaccine changes in pneumococcal epidemiology. Nat Genet 2013; 45:656-63.
24. Croucher NJ, Harris SR, Fraser C, et al. Rapid pneumococcal evolution in response to clinical interventions. Science 2011; 331:430-4.
25. Khan MN, Bansal A, Shukla D, et al. Immunogenicity and protective efficacy of DnaJ (hsp40) of Streptococcus pneumoniae against lethal infection in mice. Vaccine 2006; 24:6225-31.
26. Kanclerski K, Mollby R. Production and purification of Streptococcus pneumoniae hemolysin (pneumolysin). J Clin Microbiol 1987; 25: 222-5.
27. Lu YJ, Gross J, Bogaert D, et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog 2008; 4: e1000159.
28. Davis KM, Nakamura S, Weiser JN. Nod2 sensing of lysozymedigested peptidoglycan promotes macrophage recruitment and clearance of S. pneumoniae colonization in mice. J Clin Invest 2011; 121: 3666-76.
29. Nomura L, Maino VC, Maecker HT. Standardization and optimization of multiparameter intracellular cytokine staining. Cytometry A 2008; 73:984-91.
30. Littmann M, Albiger B, Frentzen A, Normark S, Henriques-Normark B, Plant L. Streptococcus pneumoniae evades human dendritic cell surveillance by pneumolysin expression. EMBO Mol Med 2009; 1: 211-22.
31. Pido-Lopez J, Kwok WW, Mitchell TJ, Heyderman RS, Williams NA. Acquisition of pneumococci specific effector and regulatory Cd4+ T cells localising within human upper respiratory-tract mucosal lymphoid tissue. PLoS Pathog 2011; 7:e1002396.
32. Libri V, Azevedo RI, Jackson SE, et al. Cytomegalovirus infection induces the accumulation of short-lived, multifunctional CD4- +CD45RA+CD27+ T cells: the potential involvement of interleukin-7 in this process. Immunology 2011; 132:326-39.
33. Weinberger DM, Trzcinski K, Lu YJ, et al. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog 2009; 5: e1000476.
34. Hathaway LJ, Brugger SD, Morand B, et al. Capsule type of Streptococcus pneumoniae determines growth phenotype. PLoS Pathog 2012; 8: e1002574.
35. Weinberger DM, Harboe ZB, Sanders EA, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-Analysis. Clin Infect Dis 2010; 51:692-9.
36. Seyoum B, Yano M, Pirofski LA. The innate immune response to Streptococcus pneumoniae in the lung depends on serotype and host response. Vaccine 2011; 29:8002-11.
37. Marriott HM, Gascoyne KA, Gowda R, et al. Interleukin-1beta regulates CXCL8 release and influences disease outcome in response to Streptococcus pneumoniae, defining intercellular cooperation between pulmonary epithelial cells and macrophages. Infect Immun 2012; 80: 1140-9.
38. Liechti FD, Grandgirard D, Leppert D, Leib SL. Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun 2014; 82:1710-8.
39. Krone CL, Trzcinski K, Zborowski T, Sanders EA, Bogaert D. Impaired innate mucosal immunity in aged mice permits prolonged Streptococcus pneumoniae colonization. Infect Immun 2013; 81:4615-25.
40. Gessner BD, Mueller JE, Yaro S. African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adults. BMC Infect Dis 2010; 10:22.
41. Leimkugel J, Adams Forgor A, Gagneux S, et al. An outbreak of serotype 1 Streptococcus pneumoniae meningitis in northern Ghana with features that are characteristic of Neisseria meningitidis meningitis epidemics. J Infect Dis 2005; 192:192-9.
42. Gray C, Ahmed MS, Mubarak A, et al. Activation of memory Th17 cells by domain 4 pneumolysin in human nasopharynx-Associated lymphoid tissue and its association with pneumococcal carriage. Mucosal Immunol 2013; 7:705-17.
43. Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 2008; 226:57-79.
44. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol 2007; 19:281-6.
45. Zhang Z, Clarke TB, Weiser JN. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 2009; 119:1899-909.
46. Harris NL, Ronchese F. The role of B7 costimulation in T-cell immunity. Immunol Cell Biol 1999; 77:304-11.
47. Daigneault M, De Silva TI, Bewley MA, et al. Monocytes regulate the mechanism of T-cell death by inducing Fas-mediated apoptosis during bacterial infection. PLoS Pathog 2012; 8:e1002814.
48. Dockrell DH, Marriott HM, Prince LR, et al. Alveolar macrophage apoptosis contributes to pneumococcal clearance in a resolving model of pulmonary infection. J Immunol 2003; 171:5380-8.
49. Weber S, Tian H, van Rooijen N, Pirofski LA. A serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibody requires Fcgamma receptor III and macrophages to mediate protection against pneumococcal pneumonia in mice. Infect Immun 2012; 80:1314-22.
50. Ali F, Lee ME, Iannelli F, et al. Streptococcus pneumoniae-Associated human macrophage apoptosis after bacterial internalization via complement and Fcgamma receptors correlates with intracellular bacterial load. J Infect Dis 2003; 188:1119-31